ReviewJournal of molecular neuroscience : MN1993
Neuropeptides as growth and differentiation factors in general and VIP in particular.
Review in Journal of molecular neuroscience : MN, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- NeuroScale: evolutional scale-based protein language models enable prediction of neuropeptides.BMC biology · 2025Article
- Tracing the invisible mutant ADNP protein in Helsmoortel-Van der Aa syndrome patients.Scientific reports · 2024Article
- Brain-derived neurotrophic factor - a key player in the gastrointestinal system.Przeglad gastroenterologiczny · 2023Review
- mTOR Signaling, Translational Control, and the Circadian Clock.Frontiers in genetics · 2018Review
- VIP, from gene to behavior and back: summarizing my 25 years of research.Journal of molecular neuroscience : MN · 2008Article
- Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.Journal of molecular neuroscience : MN · 2003Article
- Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Protection against developmental deficiencies by a lipophilic VIP analogue.Neurochemical research · 1998Article
- Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.Proceedings of the National Academy of Sciences of the United States of America · 1996Article
- Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin?Journal of molecular neuroscience : MN · 1996Review
- A VIP hybrid antagonist: from developmental neurobiology to clinical applications.Cellular and molecular neurobiology · 1995Review
- Article
- Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene.Journal of molecular neuroscience : MN · 1993Article
- Inhibition of human neuroblastoma growth by a specific VIP antagonist.Journal of molecular neuroscience : MNArticle
- VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment.Molecular neurobiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the course of neurodevelopment a large population of neurons die normally (Berg, 1982; Oppenheim et al., 1989). Are neuropeptides involved in the regulation of neuronal survival, maturation, and maintenance? The peptides are an ever growing family of neuroactive agents and this review shall emphasize VIP (vasoactive intestinal peptide [Said and Mutt, 1970; Gozes and Brenneman, 1989]), which has been shown to be involved in maturation, growth, and maintenance of neurons (Brenneman et al., 1985a, 1987, 1988, 1990, 1990b; Brenneman and Eiden, 1986; Brenneman and Nelson, 1986). Comparative actions of other neuropeptides will also be discussed.
Indexed as
Identifiers
8318354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.